NEWTON, Mass.--(BUSINESS WIRE)--Siamab Therapeutics, Inc., a biopharmaceutical company developing novel cancer immunotherapies targeting tumor-associated carbohydrate antigens (TACAs), today announced that Jeff Behrens, president and chief executive officer, will present at the 2017 BIO International Convention. The presentation will take place on Monday, June 19, 2017, at 2:30 p.m. PT, in Company Presentation Theater 3 at the San Diego Convention Center in San Diego, California.
Mr. Behrens will provide an overview of the company, its technology platform, and its novel anti-Sialyl-Tn (STn) antibodies, antibody-drug conjugates (ADCs), and anti-STn, anti-CD3 bispecific antibodies. In particular, Mr. Behrens will discuss the role of STn and myeloid derived suppressor cells (MDSCs), which express STn antigens, as promising cancer targets, and provide an overview of the company’s lead program ST1. He will also present new preclinical safety data from a non-human primate pilot study as well as preclinical efficacy data in ovarian and pancreatic PDX mouse models.
Siamab is leveraging its proprietary technology platform to discover and develop monoclonal antibody (mAb) therapeutics that bind to TACAs, a novel class of cancer-specific targets that are implicated in immune suppression, chemoresistance, and a cancer stem-cell phenotype. The company’s lead program, ST1, targets STn with high cancer specificity. STn is rarely expressed in normal tissues and highly expressed in numerous human adenocarcinomas, including ovarian, pancreatic, prostate, colon, gastric, and breast cancers. STn expression has been linked to innate immune suppression, a chemoresistant stem-cell phenotype, invasion/metastasis, and poor prognosis. ST1 is in late stage preclinical development and is expected to enter human clinical trials in 2019.
To schedule a meeting with Siamab’s management team at BIO, use the BIO One-on-One Partnering™ system for registered participants or contact Jenna Stein at email@example.com.
About Siamab Therapeutics, Inc.
Siamab Therapeutics, Inc. is a biopharmaceutical company developing novel cancer immunotherapies targeting tumor-associated carbohydrate antigens (TACAs) seen in multiple solid tumors. Siamab has developed a platform that enables the rapid discovery and development of therapeutic antibodies that bind with unprecedented specificity and affinity to this novel class of carbohydrate antigens. TACAs are an exciting cancer target class due to their cancer specificity, association with a chemoresistant phenotype, and ability to suppress immune function in the region of solid tumors. The company’s lead program, ST1, targets Sialyl-Tn (STn), a tumor specific antigen seen in multiple solid tumors, including ovarian, pancreatic, prostate and colon cancers. ST1 is in late-stage preclinical studies for the treatment of solid tumors. Visit www.siamab.com to learn more about the company.